The anti-PD-1 therapy pembrolizumab is now a routine therapeutic option in advanced NSCLC, with improved progression-free and overall survival used alone or in combination with cytotoxic chemotherapy.4 The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.